Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
Establishing Semaglutide as the reference compound for studying the receptor pharmacological consequences of GLP-1 analogue structural optimisation
Tirzepatide and Semaglutide treatments may not be appropriate for individuals who: Are pregnant, trying to become pregnant, or breastfeeding Have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome Have a history of pancreatitis or certain gastrointestinal conditions Have severe gastrointestinal symptoms including gastroparesis Have allergies or sensitivities to ingredients in the medication Do not meet medical eligibility guidelines as determined by the provider Results vary by individual
Gradual Reduction For some medications, abrupt discontinuation can cause withdrawal symptoms or rapid recurrence of the condition they are treating
Anyone with systemic or respiratory symptoms should be evaluated promptly and managed by experienced clinicians
Explore GLP-1 medication options, the GLP-1 weight loss program, tirzepatide medication options, or the tirzepatide weight loss program
US$ 20.43
US$ 22.74
US$ 24.83
US$ 24.91
